[Treatment of pulmonary arterial hypertension (PAH): recommendations of the Cologne Consensus Conference 2010].
The 2009 European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension have been adopted for Germany. The guidelines contain detailed recommendations for the treatment of pulmonary arterial hypertension (PAH). However, the practical implementation of the European Guidelines in Germany requires the consideration of several country-specific issues and already existing novel data. This requires a detailed commentary to the guidelines, and in some aspects an update already appears necessary. In June 2010, a Consensus Conference organized by the PH working groups of the German Society of Cardiology (DGK), the German Society of Respiratory Medicine (DGP) and the German Society of Pediatric Cardiology (DGPK) was held in Cologne, Germany. This conference aimed to solve practical and controversial issues surrounding the implementation of the European Guidelines in Germany. To this end, a number of working groups was initiated, one of which was specifically dedicated to the treatment of PAH. This commentary summarizes the results and recommendations of the working group on treatment of PAH.
Ghofrani
H A
HA
Abteilung Pneumologie, Medizinische Klink II, Universitätsklinikum Giessen und Marburg, Standort Giessen. ardeschir.ghofrani@innere.med.uni-giessen.de
Distler
O
O
Gerhardt
F
F
Gorenflo
M
M
Grünig
E
E
Haefeli
W E
WE
Held
M
M
Hoeper
M M
MM
Kähler
C-M
CM
Kaemmerer
H
H
Klose
H
H
Köllner
V
V
Kopp
B
B
Mebus
S
S
Meyer
A
A
Miera
O
O
Pittrow
D
D
Riemekasten
G
G
Rosenkranz
S
S
Schranz
D
D
Voswinckel
R
R
Olschewski
H
H
D000465:Algorithms; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003299:Cooperative Behavior; D004077:Digoxin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D065128:Endothelin Receptor Antagonists; D019317:Evidence-Based Medicine; D005081:Exercise Therapy; D005260:Female; D005858:Germany; D006801:Humans; D006976:Hypertension, Pulmonary / Q000235:genetics / Q000523:psychology / Q000534:rehabilitation*; D033183:Interdisciplinary Communication; D010102:Oxygen Inhalation Therapy; D010348:Patient Care Team; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D011247:Pregnancy; D011453:Prostaglandins / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use*
D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D002121:Calcium Channel Blockers; D065128:Endothelin Receptor Antagonists; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors; D011453:Prostaglandins; D014665:Vasodilator Agents; D004077:Digoxin